Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.04 | 9.75% | 0.27 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 9.75% | |
| Narrow Range Bar | Range Contraction | 9.75% | |
| Stochastic Reached Oversold | Weakness | 9.75% | |
| Below Lower BB | Weakness | 9.75% | |
| Gapped Down | Weakness | 9.75% | |
| Oversold Stochastic | Weakness | 9.75% | |
| MACD Bearish Signal Line Cross | Bearish | -0.33% | |
| Narrow Range Bar | Range Contraction | -0.33% |
| Alert | Time |
|---|---|
| Up 5% | about 23 hours ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above Lower Bollinger Band | 1 day ago |
| Up 3% | 1 day ago |
| Up 2% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Cyclerion Therapeutics, Inc. Description
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Orphan Disease Sickle Cell Disease Lung Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.75 |
| 52 Week Low | 1.7501 |
| Average Volume | 2,903 |
| 200-Day Moving Average | 3.21 |
| 50-Day Moving Average | 3.10 |
| 20-Day Moving Average | 3.17 |
| 10-Day Moving Average | 3.17 |
| Average True Range | 0.27 |
| RSI (14) | 47.37 |
| ADX | 16.25 |
| +DI | 34.82 |
| -DI | 27.72 |
| Chandelier Exit (Long, 3 ATRs) | 3.17 |
| Chandelier Exit (Short, 3 ATRs) | 3.58 |
| Upper Bollinger Bands | 3.49 |
| Lower Bollinger Band | 2.85 |
| Percent B (%b) | 0.3 |
| BandWidth | 20.05 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0337 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.30 | ||||
| Resistance 3 (R3) | 3.27 | 3.15 | 3.25 | ||
| Resistance 2 (R2) | 3.15 | 3.09 | 3.17 | 3.24 | |
| Resistance 1 (R1) | 3.10 | 3.05 | 3.13 | 3.13 | 3.22 |
| Pivot Point | 2.98 | 2.98 | 3.00 | 3.00 | 2.98 |
| Support 1 (S1) | 2.93 | 2.92 | 2.96 | 2.96 | 2.86 |
| Support 2 (S2) | 2.81 | 2.88 | 2.83 | 2.84 | |
| Support 3 (S3) | 2.76 | 2.81 | 2.83 | ||
| Support 4 (S4) | 2.79 |
